MedTrace Logo

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

NCT03713190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-09-14

No results posted yet for this study

Summary

A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)

Conditions

Interventions

COMBINATION_PRODUCT

Empagliflozin

Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.

DRUG

Placebo

A substance without specific pharmacology principles

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Stefano Del prato · University of Pisa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2020-02-15
Completion
2020-03-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713190 on ClinicalTrials.gov